Navigation Links
Daily Aspirin May Cut Cancer Deaths, Another Study Finds
Date:8/11/2012

By Steven Reinberg
HealthDay Reporter

FRIDAY, Aug. 10 (HealthDay News) -- People who take a low-dose aspirin daily may not only be helping their hearts, but also reducing their odds of dying from cancer, according to American Cancer Society researchers.

The lower risk of dying from cancer associated with aspirin, however, may not be as great as previously thought, say the authors of the large new study.

And aspirin's possible side effects -- notably the higher risk of bleeding episodes -- need to be taken into account when considering its use, they added.

"Expert committees that develop clinical guidelines will consider the totality of evidence about aspirin's risks and benefits when guidelines for aspirin use are next updated," said lead researcher Eric Jacobs, the society's strategic director of pharmacoepidemiology.

Jacobs said, until there are new guidelines, he doesn't recommend taking aspirin for cancer prevention.

"Although recent evidence about aspirin use and cancer is encouraging, it is still premature to recommend people start taking aspirin specifically to prevent cancer," he said.

Even low-dose aspirin can substantially increase the risk of serious gastrointestinal bleeding, Jacobs pointed out.

"Decisions about aspirin use should be made by balancing the risks against the benefits in the context of each individual's medical history. Any decision about daily aspirin use should be made only in consultation with a health care professional," he added.

The study was published in the Aug. 10 online issue of the Journal of the National Cancer Institute.

To look at the potential effect of daily aspirin use on cancer deaths, Jacobs' team used data from the Cancer Prevention Study II Nutrition Cohort, part of a larger long-term study on the effects of lifestyle factors on mortality.

This study included more than 100,000 men and women without a history of cancer, some of whom were taking aspirin daily.

Of the study participants, 5,138 eventually died from cancer.

Aspirin use was associated with an up to 16 percent lower risk of dying from cancer, which, however, was less than seen in another recent study, the researchers noted. In that analysis of randomized trials (where people were randomly assigned to either take aspirin or not take aspirin), aspirin use reduced cancer deaths by 37 percent during five years of follow-up and 15 percent during 10 years of follow-up, the authors noted in the report.

Nevertheless, "even a relatively modest benefit with respect to overall cancer mortality could still meaningfully influence the balances of risk and benefits of prophylactic [preventative] aspirin use," Jacobs' team concluded.

A limitation of the study is that it was an observational study, not a randomized trial. This could mean that the reduction in cancer deaths tied to aspirin use may be over- or under-estimated, the researchers noted.

Dr. John Baron, a professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, who authored an accompanying journal editorial, said, "It's a remarkable idea that something that's in medicine cabinets around the world, and has been around for more than a century, can prevent cancer."

However, Baron is not recommending that people start taking aspirin to cut their odds for malignancy.

Why it works against cancer isn't known, Baron said, and he noted that the effect of aspirin is seen over time. For example, aspirin might start preventing colon cancer after a person had taken it for about 10 years.

During that time, however, that person might have gastrointestinal or brain bleeding caused by aspirin. So those risks and benefits need to be balanced, he noted.

The question is no longer whether aspirin prevents cancer, according to Baron, but rather whether the risks associated with aspirin are overshadowed by its benefits, he suggested. "But even the most pessimistic study shows a meaningful reduction," he added.

But while the new study found an association between aspirin use and reduced cancer risk, because it is not a randomized, controlled trial -- the "gold standard" for research -- it did not prove a cause-and-effect relationship.

More information

To learn more about aspirin and cancer, visit the U.S. National Cancer Institute.

SOURCES: Eric J. Jacobs, Ph.D., strategic director, pharmacoepidemiology, American Cancer Society; John A. Baron, M.D., professor of medicine, University of North Carolina at Chapel Hill School of Medicine; Aug. 10, 2012, Journal of the National Cancer Institute


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Daily aspirin usage associated with lower cancer mortality
2. Study adds to evidence daily aspirin linked to lower cancer mortality
3. Intuitive Number Sense Makes Daily Life Easier
4. Some Diabetics May Not Benefit From Daily Aspirin
5. Daily Coffee May Help Keep Grim Reaper Away
6. How the brains daily clock controls mood: A new project
7. U.S. Children Exposed to Hours of Background TV Daily
8. Women Less Apt Than Men to Get Recommended Daily Exercise
9. Aspirin protects against Barretts esophagus
10. Aspirin as Effective as Warfarin for Heart Failure: Study
11. Report says new evidence could tip the balance in aspirin cancer prevention care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Daily Aspirin May Cut Cancer Deaths, Another Study Finds
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology: